A new hormonal therapy for prostatic cancer: long-term clinical and hormonal response.
Twenty-four patients with advanced prostatic cancer were treated with daily injections of the LHRH analogue ICI 118630 (Zoladex) for up to 2 1/2 years. Successful long-term suppression of LH (luteinising hormone) and testosterone was observed without any escape of testosterone. Immunoreactive LH concentrations rose significantly following the daily injection of LHRH analogue but there was no corresponding rise in testosterone concentrations, suggesting altered bioactivity of the LH. A long-term clinical response was obtained in 10 patients (41.6%) and the median duration of response in these patients was 25 months. Eight of the 10 had well to moderately differentiated tumours. The actuarial median survival of all patients was 22 months.
D000368:Aged; D000369:Aged, 80 and over; D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017273:Goserelin; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D013739:Testosterone / Q000097:blood; D013997:Time Factors
D017273:Goserelin; D013739:Testosterone; D007986:Luteinizing Hormone; D002064:Buserelin